CL2017002728A1 - Método para el tratamiento de cáncer - Google Patents

Método para el tratamiento de cáncer

Info

Publication number
CL2017002728A1
CL2017002728A1 CL2017002728A CL2017002728A CL2017002728A1 CL 2017002728 A1 CL2017002728 A1 CL 2017002728A1 CL 2017002728 A CL2017002728 A CL 2017002728A CL 2017002728 A CL2017002728 A CL 2017002728A CL 2017002728 A1 CL2017002728 A1 CL 2017002728A1
Authority
CL
Chile
Prior art keywords
troncal
mutation
antigen
cancer treatment
neo
Prior art date
Application number
CL2017002728A
Other languages
English (en)
Inventor
Nicholas Mcgranahan
Rachel Rosenthal
Charles Swanton
Karl Peggs
Sergio Quezada
Original Assignee
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1507100.4A external-priority patent/GB201507100D0/en
Priority claimed from GBGB1603663.4A external-priority patent/GB201603663D0/en
Priority claimed from GBGB1603731.9A external-priority patent/GB201603731D0/en
Application filed by Cancer Research Tech Ltd filed Critical Cancer Research Tech Ltd
Publication of CL2017002728A1 publication Critical patent/CL2017002728A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464401—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/505—CD4; CD8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Abstract

<p>LA PRESENTE INVENCIÓN SE REFIERE A UN MÉTODO PARA IDENTIFICAR UN NEO-ANTÍGENO TRONCAL EN UN TUMOR DE UN SUJETO, QUE COMPRENDE LOS PASOS DE: I) DETERMINAR LAS MUTACIONES PRESENTES EN UNA MUESTRA ASILADA DEL TUMOR; Y II) IDENTIFICAR UNA MUTACIÓN TRONCAL QUE ES UNA MUTACIÓN PRESENTE EN ESENCIALMENTE TODAS LAS CÉLULAS TUMORALES: Y III) IDENTIFICAR UN NEO-ANTÍGENO TRONCAL, QUE ES UN ANTÍGENO CODIFICADO POR UNA SECUENCIA QUE COMPRENDE MUTACIÓN TRONCAL.</p>
CL2017002728A 2015-04-27 2017-10-26 Método para el tratamiento de cáncer CL2017002728A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1507100.4A GB201507100D0 (en) 2015-04-27 2015-04-27 Method
GBGB1603663.4A GB201603663D0 (en) 2016-03-02 2016-03-02 Method
GBGB1603731.9A GB201603731D0 (en) 2016-03-03 2016-03-03 Method

Publications (1)

Publication Number Publication Date
CL2017002728A1 true CL2017002728A1 (es) 2018-06-22

Family

ID=55809140

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2017002728A CL2017002728A1 (es) 2015-04-27 2017-10-26 Método para el tratamiento de cáncer
CL2020001730A CL2020001730A1 (es) 2015-04-27 2020-06-24 Método para el tratamiento de cáncer. (divisional solicitud 201702728)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2020001730A CL2020001730A1 (es) 2015-04-27 2020-06-24 Método para el tratamiento de cáncer. (divisional solicitud 201702728)

Country Status (22)

Country Link
US (3) US20180064793A1 (es)
EP (4) EP3288581B1 (es)
JP (4) JP6918703B2 (es)
KR (2) KR102629590B1 (es)
CN (2) CN107750278B (es)
AU (2) AU2016256220B2 (es)
BR (1) BR112017020893A2 (es)
CA (1) CA2982266A1 (es)
CL (2) CL2017002728A1 (es)
DK (1) DK3288581T3 (es)
ES (1) ES2836273T3 (es)
HU (1) HUE052106T2 (es)
IL (2) IL298497A (es)
MX (1) MX2017013777A (es)
MY (1) MY189338A (es)
NZ (1) NZ735882A (es)
PL (1) PL3288581T3 (es)
PT (1) PT3288581T (es)
RU (2) RU2770447C2 (es)
SG (2) SG10202007364RA (es)
WO (1) WO2016174085A1 (es)
ZA (1) ZA201706616B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
IL259931B2 (en) 2015-12-16 2024-02-01 Gritstone Bio Inc Identification of neo-antigens, preparation, and use
US20170224796A1 (en) 2016-02-05 2017-08-10 Xeme Biopharma Inc. Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System
CA3044250A1 (en) * 2016-11-17 2018-05-24 Iovance Biotherapeutics, Inc. Remnant tumor infiltrating lymphocytes and methods of preparing and using the same
EP3548897A4 (en) 2016-12-01 2020-08-12 Nantomics, LLC PRESENTATION AND TREATMENT OF TUMOR ANTIGENICITY
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
EP3579846A1 (en) * 2017-02-07 2019-12-18 Memorial Sloan Kettering Cancer Center Use of immune checkpoint modulators in combination with antigen-specific t cells in adoptive immunotherapy
WO2018183980A2 (en) 2017-03-31 2018-10-04 Pei Jia Yang Ranking system for immunogenic cancer-specific epitopes
CN110913896A (zh) 2017-07-14 2020-03-24 弗朗西斯.克里克研究所 肿瘤中hla等位基因的分析及其用途
AU2018348165A1 (en) 2017-10-10 2020-05-21 Gritstone Bio, Inc. Neoantigen identification using hotspots
KR20200090855A (ko) 2017-11-22 2020-07-29 그릿스톤 온콜로지, 인코포레이티드 신생항원에 대한 접합 에피토프 제시 감소
EP3618071A1 (en) * 2018-08-28 2020-03-04 CeCaVa GmbH & Co. KG Methods for selecting tumor-specific neoantigens
WO2020043805A1 (en) * 2018-08-28 2020-03-05 CeCaVa GmbH & Co. KG Methods for ranking and/or selecting tumor-specific neoantigens
CN109337873A (zh) * 2018-09-30 2019-02-15 北京鼎成肽源生物技术有限公司 一种lrff细胞
CN109294997B (zh) * 2018-09-30 2020-09-25 北京鼎成肽源生物技术有限公司 一种lrfft1细胞
CN109295097B (zh) * 2018-09-30 2020-09-25 北京鼎成肽源生物技术有限公司 一种mrfft2细胞
CN109485721A (zh) * 2018-11-23 2019-03-19 杜学明 一种获得肿瘤特异性t细胞受体的方法
AU2020204779A1 (en) * 2019-01-03 2021-08-26 Evaxion Biotech A/S Vaccines targeting neoepitopes
CN110534156B (zh) * 2019-09-02 2022-06-17 深圳市新合生物医疗科技有限公司 一种提取免疫治疗新抗原的方法及系统
CN110689930B (zh) * 2019-10-18 2021-07-30 北京橡鑫生物科技有限公司 检测tmb的方法及装置
WO2021087839A1 (zh) * 2019-11-07 2021-05-14 武汉华大吉诺因生物科技有限公司 肿瘤特异性多肽序列及其应用
WO2021116714A1 (en) * 2019-12-12 2021-06-17 Achilles Therapeutics Uk Limited Method for obtaining nucleic acid for sequencing
WO2021123832A1 (en) 2019-12-20 2021-06-24 Instil Bio (Uk) Limited Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
US20230235008A1 (en) * 2020-02-14 2023-07-27 H. Lee Moffitt Cancer Center And Research Institute, Inc. Novel t cell receptors (tcrs) that react to neoantigens
CN111303268B (zh) * 2020-03-10 2021-08-27 江苏兰恩生物治疗技术研究院有限公司 子宫肌瘤新抗原、其应用和子宫肌瘤疫苗
JP2022024683A (ja) 2020-07-28 2022-02-09 株式会社ミツトヨ 形状測定方法
GB202104715D0 (en) * 2021-04-01 2021-05-19 Achilles Therapeutics Uk Ltd Identification of clonal neoantigens and uses thereof
GB202202880D0 (en) 2022-03-02 2022-04-13 Achilles Therapeutics Uk Ltd Methods for peptide synthesis
GB202205147D0 (en) 2022-04-07 2022-05-25 Achilles Therapeutics Uk Ltd Identification of clonal neoantigens and uses thereof
GB202205135D0 (en) 2022-04-07 2022-05-25 Francis Crick Institute Ltd Analysis of HLA alleles transcriptional deregulation
WO2023194491A1 (en) 2022-04-07 2023-10-12 The Francis Crick Institute Limited Analysis of hla alleles transcriptional deregulation
GB202210006D0 (en) 2022-07-07 2022-08-24 Achilles Therapeutics Uk Ltd Analysis of T cell samples
WO2024034622A1 (ja) * 2022-08-08 2024-02-15 北海道公立大学法人 札幌医科大学 対象由来のネオアンチゲンを選択するための方法
GB202213928D0 (en) 2022-09-23 2022-11-09 Achilles Therapeutics Uk Ltd Allele specific expression

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2209633C2 (ru) * 1997-09-19 2003-08-10 Юниверсити Оф Саузерн Калифорниа Т-клеточная вакцина для лечения рассеянного склероза
AU3483001A (en) * 2000-02-04 2001-08-14 Corixa Corp Compositions and methods for the therapy and diagnosis of ovarian cancer
US9115402B2 (en) * 2010-05-14 2015-08-25 Dana-Farber Cancer Institute, Inc. Compositions and methods of identifying tumor specific neoantigens
FI3892295T3 (fi) * 2011-05-24 2023-05-10 BioNTech SE Yksilöityjä rokotteita syöpää varten
JP2015533473A (ja) * 2012-07-12 2015-11-26 ペルシミューン，インコーポレイテッド 個別のがんワクチン及び適応免疫細胞療法
WO2014026096A1 (en) * 2012-08-10 2014-02-13 The Broad Institute, Inc. Methods and apparatus for analyzing and quantifying dna alterations in cancer
ES2824024T3 (es) 2012-10-10 2021-05-11 Sangamo Therapeutics Inc Compuestos modificadores de células T y usos de los mismos
BR112015025460B1 (pt) * 2013-04-07 2024-01-02 The Broad Institute, Inc. Método para a produção de uma vacina personalizada contra a neoplasia para um indivíduo diagnosticado como tendo uma neoplasia, vacina personalizada e uso da mesma
WO2015014375A1 (en) * 2013-07-30 2015-02-05 Biontech Ag Tumor antigens for determining cancer therapy
GB201319446D0 (en) * 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
CA2934073A1 (en) * 2013-12-20 2015-06-25 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
TWI755157B (zh) * 2015-03-17 2022-02-11 德商英麥提克生物技術股份有限公司 用於抗胰臟癌與其他癌症的免疫治療的新穎胜肽及胜肽的組合
GB201516047D0 (en) * 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method

Also Published As

Publication number Publication date
RU2770447C2 (ru) 2022-04-18
KR102629590B1 (ko) 2024-01-24
AU2016256220A1 (en) 2017-10-19
MX2017013777A (es) 2018-03-27
SG10202007364RA (en) 2020-09-29
RU2017134504A (ru) 2019-04-04
IL298497A (en) 2023-01-01
CA2982266A1 (en) 2016-11-03
CN107750278B (zh) 2023-10-03
JP2018520637A (ja) 2018-08-02
JP2024001069A (ja) 2024-01-09
PT3288581T (pt) 2020-12-04
HUE052106T2 (hu) 2021-04-28
BR112017020893A2 (pt) 2018-07-10
EP3603666A1 (en) 2020-02-05
US20180064793A1 (en) 2018-03-08
WO2016174085A1 (en) 2016-11-03
NZ735882A (en) 2022-07-29
JP2022008381A (ja) 2022-01-13
ES2836273T3 (es) 2021-06-24
ZA201706616B (en) 2021-03-31
RU2020123735A (ru) 2020-07-30
CL2020001730A1 (es) 2020-11-06
EP3603665A1 (en) 2020-02-05
JP6918703B2 (ja) 2021-08-11
MY189338A (en) 2022-02-04
EP4137151A1 (en) 2023-02-22
DK3288581T3 (da) 2021-01-11
US20200000904A1 (en) 2020-01-02
SG11201707920YA (en) 2017-11-29
IL254760B1 (en) 2023-01-01
CN117467603A (zh) 2024-01-30
RU2017134504A3 (es) 2020-08-12
AU2016256220B2 (en) 2021-10-21
KR20230125090A (ko) 2023-08-28
EP3288581B1 (en) 2020-11-11
IL254760A (en) 2017-12-31
JP2020127404A (ja) 2020-08-27
EP3288581A1 (en) 2018-03-07
CN107750278A (zh) 2018-03-02
IL254760B2 (en) 2023-05-01
US20200000903A1 (en) 2020-01-02
PL3288581T3 (pl) 2021-05-31
KR20170138560A (ko) 2017-12-15
AU2021286241A1 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
CL2017002728A1 (es) Método para el tratamiento de cáncer
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
CY1123459T1 (el) Χρηση των κανναβινοειδων στη θεραπεια του συμπλεγματος οζωδους σκληρυνσης
ECSP17070399A (es) Anticuerpos contra icos
CL2017002241A1 (es) Método de tratamiento de cáncer asociado con una mutación de ras
CL2019000061A1 (es) Anticuerpo para anti-claudin 18a2 y su utilización.
SV2018005684A (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
CL2017003456A1 (es) Metodos para tratar tumores de celulas epitelioides
CL2021001506A1 (es) Anticuerpos que se unen a cd3
CL2017000285A1 (es) Terapia combinada para el tratamiento de un paramixovirus
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
BR112017013176A2 (pt) receptores de antígenos quiméricos e métodos para usá-los
CL2017002786A1 (es) Referencia cruzada a solicitudes relacionadas
CL2016001708A1 (es) Determinantes de respuesta del cáncer a la inmunoterapia
CL2018000596A1 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
AR097481A1 (es) Cocristales energéticos para el tratamiento de una formación subterránea
AR097032A1 (es) Hidrogeles de poli(alquenilamida)-polisacárido para el tratamiento de formaciones subterráneas
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CO2019000753A2 (es) Métodos para tratar el cáncer de próstata
PE20220297A1 (es) Neutralizacion del virus chikungunya mediada por anticuerpos
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
EA201890442A1 (ru) Получение фоторецепторов для лечения заболеваний сетчатки
CL2015002723A1 (es) Métodos para tratar la psoriasis utilizando un anticuerpo anti-il-23
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
CO2017000950A2 (es) Compuestos que comprenden oligonucleótidos modificados dirigidos a mir-103 y/o mir-107 para trastornos metabólicos